伊拉克库尔德斯坦-埃尔比勒地区SARS-CoV-2疫苗接种后IgG和IgM的血清学研究

Q3 Veterinary
M Y Merza
{"title":"伊拉克库尔德斯坦-埃尔比勒地区SARS-CoV-2疫苗接种后IgG和IgM的血清学研究","authors":"M Y Merza","doi":"10.32592/ARI.2025.80.1.249","DOIUrl":null,"url":null,"abstract":"<p><p>The ongoing global pandemic of coronavirus disease (Covid-19) has had a considerable impact on healthcare systems and economies worldwide. The aim of vaccines against the virus is to elicit an immune response against the spike protein of the SARS-CoV-2 virus, with the objective of neutralizing the virus. Efficacy has now been demonstrated for several vaccinations, including those based on mRNA, adenoviral-vectored protein subunits, and whole-cell inactivated subunits. A comprehensive understanding of the immune responses to these vaccines, and the manner in which different antibodies are generated following vaccination, is imperative to enhance our comprehension of the pathophysiology of the disease. The present study aims to provide a comparative analysis of the humoral immune responses elicited by BNT162b2 (mRNA-based), BBIBP-CorV (inactivated virus), and ChAdOx1 (dsDNA-recombinant) vaccines against the SARS-CoV-2 virus. The study population comprised 321 individuals, with 90 individuals who had not received any vaccines (control group) and 77 individuals who had received the Pfizer and Sinopharm vaccines, respectively. Blood samples were collected 10 weeks after vaccination, and serum analysis was performed. The human SARS-CoV-2 Spike (Trimer) IgG or IgM ELISA (Thermo Fisher) was utilized to assess the quantity of IgG or IgM antibodies that had bound to the SARS-CoV-2 Spike (Trimer). The study revealed that there was no statistically significant difference between the vaccines (P value = 0.958). The investigation further demonstrated that all three vaccines (Pfizer, AstraZeneca and Sinopharm) were effective in stimulating the production of IgM and IgG. The study revealed that Sinopharm demonstrated superior efficacy in the induction of IgM and IgG. The utilization of ChAdOx1 resulted in the generation of higher levels of IgG compared to BNT162b2, as evidenced by a statistically significant difference (P value= 0.0001). The enhanced immune response observed with Sinopharm could be attributed to its nature as an inactivated subunit vaccine. The immunological reactions to the vaccines studied in the following studies have prompted a lot of issues about how they happen, and the study recommends more studies regarding the most effective vaccines among the Kurdish people in the Kurdistan Region of Iraq.</p>","PeriodicalId":8311,"journal":{"name":"Archives of Razi Institute","volume":"80 1","pages":"249-255"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426432/pdf/","citationCount":"0","resultStr":"{\"title\":\"Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq.\",\"authors\":\"M Y Merza\",\"doi\":\"10.32592/ARI.2025.80.1.249\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The ongoing global pandemic of coronavirus disease (Covid-19) has had a considerable impact on healthcare systems and economies worldwide. The aim of vaccines against the virus is to elicit an immune response against the spike protein of the SARS-CoV-2 virus, with the objective of neutralizing the virus. Efficacy has now been demonstrated for several vaccinations, including those based on mRNA, adenoviral-vectored protein subunits, and whole-cell inactivated subunits. A comprehensive understanding of the immune responses to these vaccines, and the manner in which different antibodies are generated following vaccination, is imperative to enhance our comprehension of the pathophysiology of the disease. The present study aims to provide a comparative analysis of the humoral immune responses elicited by BNT162b2 (mRNA-based), BBIBP-CorV (inactivated virus), and ChAdOx1 (dsDNA-recombinant) vaccines against the SARS-CoV-2 virus. The study population comprised 321 individuals, with 90 individuals who had not received any vaccines (control group) and 77 individuals who had received the Pfizer and Sinopharm vaccines, respectively. Blood samples were collected 10 weeks after vaccination, and serum analysis was performed. The human SARS-CoV-2 Spike (Trimer) IgG or IgM ELISA (Thermo Fisher) was utilized to assess the quantity of IgG or IgM antibodies that had bound to the SARS-CoV-2 Spike (Trimer). The study revealed that there was no statistically significant difference between the vaccines (P value = 0.958). The investigation further demonstrated that all three vaccines (Pfizer, AstraZeneca and Sinopharm) were effective in stimulating the production of IgM and IgG. The study revealed that Sinopharm demonstrated superior efficacy in the induction of IgM and IgG. The utilization of ChAdOx1 resulted in the generation of higher levels of IgG compared to BNT162b2, as evidenced by a statistically significant difference (P value= 0.0001). The enhanced immune response observed with Sinopharm could be attributed to its nature as an inactivated subunit vaccine. The immunological reactions to the vaccines studied in the following studies have prompted a lot of issues about how they happen, and the study recommends more studies regarding the most effective vaccines among the Kurdish people in the Kurdistan Region of Iraq.</p>\",\"PeriodicalId\":8311,\"journal\":{\"name\":\"Archives of Razi Institute\",\"volume\":\"80 1\",\"pages\":\"249-255\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426432/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Razi Institute\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32592/ARI.2025.80.1.249\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Veterinary\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Razi Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32592/ARI.2025.80.1.249","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Veterinary","Score":null,"Total":0}
引用次数: 0

摘要

持续的冠状病毒病(Covid-19)全球大流行对世界各地的卫生保健系统和经济产生了相当大的影响。针对该病毒的疫苗的目的是引发针对SARS-CoV-2病毒刺突蛋白的免疫反应,目的是中和该病毒。目前已证实几种疫苗的有效性,包括基于mRNA、腺病毒载体蛋白亚基和全细胞灭活亚基的疫苗。全面了解对这些疫苗的免疫反应,以及接种疫苗后产生不同抗体的方式,对于增强我们对疾病病理生理学的理解是必不可少的。本研究旨在比较分析BNT162b2 (mRNA-based)、BBIBP-CorV(灭活病毒)和ChAdOx1 (dsdna -重组)疫苗对SARS-CoV-2病毒的体液免疫反应。研究人群共有321人,其中90人未接种任何疫苗(对照组),77人分别接种了辉瑞和国药集团的疫苗。接种后10周采集血样,进行血清分析。采用人SARS-CoV-2刺状蛋白(三聚体)IgG或IgM ELISA (Thermo Fisher)检测与SARS-CoV-2刺状蛋白(三聚体)结合的IgG或IgM抗体数量。研究结果显示,两种疫苗之间的差异无统计学意义(P值= 0.958)。调查进一步表明,所有三种疫苗(辉瑞、阿斯利康和国药)都能有效刺激IgM和IgG的产生。研究显示国药对IgM和IgG的诱导效果较好。与BNT162b2相比,利用ChAdOx1可产生更高水平的IgG,差异有统计学意义(P值= 0.0001)。在国药组观察到的增强免疫反应可归因于其灭活亚单位疫苗的性质。在接下来的研究中,对疫苗的免疫反应引发了很多关于它们如何发生的问题,该研究建议对伊拉克库尔德斯坦地区库尔德人中最有效的疫苗进行更多的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Serological Studies of IgG and IgM in Response to SARS-CoV-2 Vaccination in Erbil, Kurdistan-Iraq.

The ongoing global pandemic of coronavirus disease (Covid-19) has had a considerable impact on healthcare systems and economies worldwide. The aim of vaccines against the virus is to elicit an immune response against the spike protein of the SARS-CoV-2 virus, with the objective of neutralizing the virus. Efficacy has now been demonstrated for several vaccinations, including those based on mRNA, adenoviral-vectored protein subunits, and whole-cell inactivated subunits. A comprehensive understanding of the immune responses to these vaccines, and the manner in which different antibodies are generated following vaccination, is imperative to enhance our comprehension of the pathophysiology of the disease. The present study aims to provide a comparative analysis of the humoral immune responses elicited by BNT162b2 (mRNA-based), BBIBP-CorV (inactivated virus), and ChAdOx1 (dsDNA-recombinant) vaccines against the SARS-CoV-2 virus. The study population comprised 321 individuals, with 90 individuals who had not received any vaccines (control group) and 77 individuals who had received the Pfizer and Sinopharm vaccines, respectively. Blood samples were collected 10 weeks after vaccination, and serum analysis was performed. The human SARS-CoV-2 Spike (Trimer) IgG or IgM ELISA (Thermo Fisher) was utilized to assess the quantity of IgG or IgM antibodies that had bound to the SARS-CoV-2 Spike (Trimer). The study revealed that there was no statistically significant difference between the vaccines (P value = 0.958). The investigation further demonstrated that all three vaccines (Pfizer, AstraZeneca and Sinopharm) were effective in stimulating the production of IgM and IgG. The study revealed that Sinopharm demonstrated superior efficacy in the induction of IgM and IgG. The utilization of ChAdOx1 resulted in the generation of higher levels of IgG compared to BNT162b2, as evidenced by a statistically significant difference (P value= 0.0001). The enhanced immune response observed with Sinopharm could be attributed to its nature as an inactivated subunit vaccine. The immunological reactions to the vaccines studied in the following studies have prompted a lot of issues about how they happen, and the study recommends more studies regarding the most effective vaccines among the Kurdish people in the Kurdistan Region of Iraq.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Razi Institute
Archives of Razi Institute Veterinary-Veterinary (all)
CiteScore
1.50
自引率
0.00%
发文量
108
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信